Journal
MABS
Volume 5, Issue 1, Pages 34-46Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.22775
Keywords
monoclonal antibodies; immune cells; cancer; accumulation; affinity; therapy; mechanism of action; ADCC
Categories
Funding
- Italian Association for Cancer Research (AIRC, Milan) [9965, IG11692, IG9180]
- Ministry of Health (Rome)
- Ministry of University and Research (Rome)
Ask authors/readers for more resources
Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses to mAb therapy, however, are far from optimal, with many patients presenting native or acquired resistance or suboptimal responses to a mAb therapy. MAbs exert antitumor activity through different mechanisms of action and we propose here a classification of these mechanisms. In many cases mAbs need to interact with immune cells to exert antitumor activity. We summarize evidence showing that interactions between mAbs and immune cells may be inadequate for optimal antitumor activity. This may be due to insufficient tumor accumulation of mAbs or immune cells, or to low-affinity interactions between these components. The possibilities to improve tumor accumulation of mAbs and immune cells, and to improve the affinity of the interactions between these components are reviewed. We also discuss future directions of research that might further improve the therapeutic efficacy of antitumor mAbs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available